title: Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma.
abstract: OBJECTIVE
  To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy.
  
  
  METHODS
  The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy.
  
  
  RESULTS
  M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate (24.9% vs 65.5%; P=0.04) and the disease-free survival rate (17.8% vs 59.3%; P=0.03).
  
  
  CONCLUSIONS
  These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
authors.affiliation: Department of Radiation Oncology, The Catholic University of Korea, School of Medicine, Seoul, Korea.
authors.forename: Hong Seok
authors.initials: HS
authors.lastname: Jang
authors.forename: Ki Mun
authors.initials: KM
authors.lastname: Kang
authors.forename: Byung Ock
authors.initials: BO
authors.lastname: Choi
authors.forename: Gyu Young
authors.initials: GY
authors.lastname: Chai
authors.forename: Soon Chan
authors.initials: SC
authors.lastname: Hong
authors.forename: Woo Song
authors.initials: WS
authors.lastname: Ha
authors.forename: Randy L
authors.initials: RL
authors.lastname: Jirtle
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D019656:Loss of Heterozygosity / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D017527:Receptor, IGF Type 2 / Q000235:genetics*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D017527:Receptor, IGF Type 2